Abstract. Temozolomide (TMZ) is an alkylating agent that has yielded significant benefits and is a current standard agent in the treatment of malignant gliomas. However, its survival benefit remains unsatisfactory. Recently, a synergistic antitumor effect between TMZ and interferon-β (IFN-β) was reported in malignant glioma cells. The Japan Clinical Oncology Group (JCOG) brain tumor study group has recently began a randomized phase II study to evaluate the clinical effectiveness of combination therapy with TMZ and IFN-β in glioblastomas. However, it is not sufficient just to evaluate the mechanisms and establish an experimental basis for rational clinical therapy with IFN-β and TMZ. The precise mechanisms governing the direct effects of IFN-β and a combination of IFN-β and TMZ in gliomas are not yet fully understood. To gain insight into the mechanisms of sensitivity/resistance involving IFN-β and combination therapy with IFN-β and TMZ, and further to identify new marker(s) that could be used clinically to predict the response to such therapy and new target gene(s) for therapies related to malignant glioma patho genesis, we evaluated the gene expression profiles of human malignant glioma cell lines employing a high-density oligo nucleotide DNA array, GeneChip. We present a list of the most highly upregulated and downregulated genes which may be involved in conferring a response to IFN-β and synergistic effect between IFN-β and TMZ in malignant gliomas. Although the present study has several limitations, our reported candidate genes could represent not only potential molecular markers but also chemotherapy targets for improving the treatment outcome by devising strategies that are able to circumvent primary drug resistance in malignant gliomas.
Introduction
Malignant gliomas, especially glioblastomas, are the most frequently occurring primary tumors of the central nervous system and constitute one of the most aggressive and lethal malignancies. They continue to present an enormous therapeutic challenge, because multimodality treatments including extensive tumor resection, radiotherapy and chemotherapy have afforded little improvement to the poor prognosis for more than three decades.
Recently, the European Organisation for Research and Treatment of Cancer (EORTC)/National Cancer Institute of Canada Clinical Trial Group (NCIC) reported final results indicating that the benefits of concomitant and adjuvant temozolomide (TMZ) in addition to standard postoperative radiotherapy as the first-line treatment for glioblastomas lasted throughout 5 years of follow-up; the overall survival was 9.8% at 5 years with TMZ versus 1.9% with radiotherapy alone (1) . Concomitant radiotherapy with TMZ followed by adjuvant TMZ chemotherapy has thus become a current standard treatment for malignant gliomas, especially glioblastomas. However, the prognosis remains unsatisfactory, and the establishment of a more effective regimen of TMZ therapy is needed. The limited efficacy of chemotherapy can be attributed largely to both inherent and acquired tumor drug resistance mechanisms. Among the factors that may contribute to the TMZ resistance, O 6 -methylguanine-DNA methyltransferase (MGMT, a protein that removes drug-induced alkylguanine adducts from DNA created by TMZ) is thought to be involved in its principal mechanisms (1, 2) . In addition, we more recently reported a list of the most highly upregulated and downregulated genes which may be involved in conferring TMZ sensitivity/resistance in malignant gliomas employing a cDNA microarray, and suggested that an elevated level of the MGMT gene is one of the most robust predictors of the TMZ response in malignant glioma cells in vitro (3) .
Human interferon-β (IFN-β), which belongs to the type I IFNs, was first discovered on the basis of its antiviral activities. Subsequently, it was shown to exhibit pleiotropic biological activities including an immunomodulatory activity, antiangiogenetic activity and direct antitumor effects: e.g., growth inhibition, apoptosis, etc. (4-6). In addition to such multiple
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functions of IFN-β against human neoplasias, it can act as a drug sensitizer enhancing the toxicity when given in combination with nitrosoureas (alkylating agents) in the treatment of malignant gliomas (7) . It is therefore widely employed either alone or in combination with other antitumor agents such as nitrosoureas in the treatment of gliomas, particularly in Japan (4, (7) (8) (9) . Recently, a synergistic antitumor effect between TMZ and IFN-β was reported in malignant glioma cells in vitro (10, 11) . Natsume et al suggested that a sensitizing effect between IFN-β and TMZ in TMZ-resistant glioma cells was possibly due to an attenuation of MGMT expression via induction of the protein p53 (10) . Furthermore, we demonstrated that a significant synergistic antitumor effect and downregulated quantitative MGMT mRNA levels were observed when TMZ was combined with IFN-β at clinically relevant concentrations, as compared to treatment with TMZ or IFN-β alone in TMZ-resistant glioma cells, and that significant amounts of endogenous IFN-β protein were detected in the TMZ-treated cells by ELISA (12) .
These findings indicated that favorable therapeutic interactions might take place between IFN-β and TMZ, and that combination therapy with IFN-β and TMZ might further improve the clinical outcome in malignant gliomas as compared to TMZ chemotherapy alone. Currently, a clinical study is being conducted in order to evaluate the clinical effectiveness of a combination of IFN-β and TMZ in glioblastomas: integrated Japanese multicenter clinical trial: a phase II study of interferon-β and temozolomide for glioma in combination with radiotherapy (INTEGRA Study) (13) . However, it is not sufficient just to evaluate the mechanisms and establish an experimental basis for rational clinical therapy with IFN-β and TMZ. The precise mechanisms governing the direct effects of IFN-β and a combination of IFN-β and TMZ in gliomas are not yet fully understood.
Sensitivity/resistance to tumor chemotherapy may be very complex and often multifactorial with numerous genes involved. With the recent development of high-density oligonucleotide DNA array technology, the global gene expression profile can be analyzed simultaneously (14) . In addition to the identification of new classes of human malignancies, this powerful method has become widely applied in an attempt to increase our understanding of chemotherapy sensitivity/resistance and to provide additional information on the underlying tumor biology that can be used to guide therapeutic strategies (15, 16) . As mentioned above, we reported previously a list of genes that may confer TMZ sensitivity/resistance in malignant gliomas employing a cDNA microarray. Furthermore, to gain new insight into the mechanisms of sensitivity/resistance involving IFN-β and combination therapy with IFN-β and TMZ in malignant gliomas, and to identify new marker(s) that could predict the response to therapy and new target gene(s) for the therapy related to malignant glioma pathogenesis, we evaluated the gene expression profiles of human malignant glioma cell lines employing the GeneChip high-density oligonucleotide DNA array technology.
Materials and methods

Tumor cell lines.
Human malignant glioma A-172, AM-38, T98G, U-251MG and YH-13 cells were purchased from Health Science Research Resources Bank (Sennan, Osaka, Japan) and U-87MG and U-138MG cells were purchased from the American Tissue Culture Collection (ATCC; Manassas, VA, USA). Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco BRL) in a standard humidified incubator at 37˚C under a 5% CO 2 95% air atmosphere.
Cell culture growth studies with IFN-β and a combination of TMZ and IFN-β.
Growth inhibitory effect of IFN-β. The sensitivities of the seven glioma cell lines to IFN-β were evaluated from the concentration required for 75% growth inhibition (IC 75 ) in comparison with untreated controls. Briefly, cells were plated at 2x10 4 cells per well in 24-well, flat-bottomed plates and incubated with medium for 24 h. The cells were subsequently washed twice with medium and incubated further with fresh medium containing 0.1-1,000 IU/ml of IFN-β or medium (control). After exposure to the various concentrations of IFN-β for 72 h, cells were detached by trypsinization and the numbers counted. The experiments were repeated at least four times at each concentration.
Combined effect of TMZ and IFN-β. To assess the antitumor effect of a combination of TMZ and IFN-β, we investigated the following incubation conditions: 10 µM TMZ, 10 IU/ml IFN-β, or 10 µM TMZ and 10 IU/ml IFN-β. These conditions represent the relevant concentrations of TMZ and IFN-β (12) . Briefly, cells were plated at 2x10 4 cells per well in 24-well, flat-bottomed plates and incubated with medium for 24 h. The cells were subsequently washed twice with medium and incubated further with fresh medium (control), or medium containing 10 µM TMZ, 10 IU/ml IFN-β, or 10 µM TMZ and 10 IU/ml IFN-β for 72 h. After exposure to the various conditions for 72 h, cells were detached by trypsinization and the numbers counted. The experiments were repeated six times at each concentration.
RNA preparation and hybridization to GeneChip array. The cell lines were subjected to an assessment of their gene expression profile using a high-density oligonucleotide array (GeneChip array; Affymetrix, Santa Clara, CA, USA) as described previously (17) . Briefly, the extracted total RNA was purified with an RNeasy Mini Kit (Qiagen, Valencia, CA), quantified by spectrophotometry, and analyzed by gel electrophoresis. Double-stranded cDNA was generated from the total RNA (5 µg) using a One-Cycle cDNA Synthesis Kit (Affymetrix). Biotinylated cRNA from cDNA was synthesized in an in vitro transcription reaction employing an IVT Labeling Kit (Affymetrix). The biotinylated cRNA (10 µg) was then fragmented and hybridized to a DNA oligonucleotide expression array (Affymetrix Human Genome U133A 2.0 Array) containing greater than 22,277 probe sets for ~14,500 human genes (some genes are represented on the array by multiple probe sets). The hybridized probe array was washed and stained with a streptavidin-phycoerythrin conjugate (Molecular Probe, Eugene, OR, USA) using a Fluidics Station 450 (Affymetrix), following the manufacturer's instructions.
Identification of discriminatory genes for IFN-β sensitivity.
The probe array was then scanned with a confocal laser scanner (GeneChip Scanner 3000; Affymetrix) and analyzed with Affymetrix GeneChip Operating Software 1.1 to calculate the signal intensities of the gene expression levels. All of the genes represented on the GeneChip were globally normalized and scaled to signal intensity (gene expression value) as described previously (18) . To avoid contributions from artificial sources of variation in the experimentally measured expression patterns, each cell line was grown in three independent cultures, and the entire process was carried out independently on mRNA extracted from each culture. The expression array analysis for each cell line was then run in triplicate.
To identify discriminative genes for IFN-β sensitivity/ resistance, Pearson's correlation was performed to evaluate the association between the IC 75 (19) (20) (21) . However, scarce data are available concerning the role of 2'5'OAS in malignant glioma cells. Therefore, to investigate whether or not IFN-β could induce antiviral proteins, 2'5'OAS in malignant glioma cells, the 2'5'OAS activity was determined at 24 h after incubation with IFN-β.
The 2'5'OAS activity levels in the seven malignant glioma cell lines were estimated by enzyme assay at 24 h after IFN-β treatment, using an Eiken 2-5A RIA kit (Eiken Immunochemical Laboratory, Tokyo, Japan). Briefly, pelleted cell samples (1x10 6 cells) were first lysed and incubated with polyI:C-agarose to be adsorbed and activated. Next, a mixture of 125 I-labeled 2'5'OA, the anti-2'5'OA serum, and the second antibody was added. Following incubation, the mixture was centrifugally separated, and the supernatant was removed by suction to perform the B/F separation. Finally, the radioactivity of the precipitate was measured with a well-type scintillation counter. The binding rate with respect to the initially added quantity of 125 I-labeled 2'5'OA was calculated, and the amount of 2'5'OA produced by the 2'5'OAS in the sample was obtained from the standard curve which was prepared at the same time. Enzyme activity was expressed in pmol/dl.
Identification of discriminatory genes for the synergistic effect between TMZ and IFN-β. Studies were undertaken to identify discriminative genes whose expression was related to a synergistic antitumor effect of combination therapy with TMZ and IFN-β in the seven malignant glioma cell lines. First, the cell lines were divided into two groups based on the presence or absence of a synergistic effect between TMZ and IFN-β in the cell cultures (see section on Cell culture growth studies with IFN-β and a combination of TMZ and IFN-β), confirmed with the Kruskal-Wallis H test and Mann-Whitney U test. The gene expression level of each gene was then compared and the difference calculated between two groups using the Student's t-test.
Results
We first obtained the individual IC 75 values of IFN-β (sensitivity/ resistance) from the cell growth inhibitory effects of the seven malignant glioma cell lines, and then identified the genes whose expression correlated most highly with IFN-β sensitivity/ resistance employing the GeneChip array and Pearson's correlation coefficient. Furthermore, to investigate whether or not IFN-β could induce antiviral proteins, 2'5'OAS in malignant glioma cell lines, the 2'5'OAS activity was determined at 24 h after incubation with IFN-β.
We next identified genes whose expression was related to a synergistic antitumor effect of combination therapy with TMZ and IFN-β in the malignant glioma cells. The cell lines were divided into two groups based on the presence or absence of a synergistic effect between TMZ and IFN-β, and genes were then identified whose expression levels were statistically different between the two groups. IC 75 , mean, represents the IFN-β concentration inducing a 75% decrease in cell growth as compared to the control. n.r., not reached. malignant glioma cell lines, A-172, U-251MG and YH-13, was <10 IU/ml and that for three other malignant glioma cell lines, AM-38, T98MG and U-87MG, was >10 IU/ml. U-138MG was found to be resistant to IFN-β, since the U-138MG cells did not reach their IC 75 with 0.1-1,000 IU/ml of IFN-β treatment.
Antitumor effect and IC
The IC 75 values of IFN-β for each cell line are listed in Table I .
Identification of discriminatory genes for IFN-β sensitivity.
From the total of 22,277 probe sets, no expressed gene was omitted, leaving 16,913 probe sets for subsequent analysis. Several upregulated and downregulated genes in the seven malignant glioma cell lines relative to their IFN-β sensitivity/ resistance were observed. First, the highly significant statistically negative-and positive-correlated genes associated with IFN-β sensitivity/resistance were selected from six cell lines (excluding U-138MG, because its did not reach its IC 75 with 0.1-1,000 IU/ml of IFN-β treatment). We then picked out the genes that were compatible with the signal intensity of the gene expression level in U-138MG, as listed in Tables II and  III. Pearson's correlation coefficients (r) and the corresponding P-values for these correlations are also shown in Tables II and  III (comprising positive and negative higher ranks of Pearson's correlation coefficient, of >0.85 and <-0.85, and parametric P<0.00001). The gene-specific information was retrieved from Entrez Gene: gene-centered information at NCBI (22) .
The genes that were picked out, except for PTEN (phosphatase and tensin homolog) and EIF2AK1 (eukaryotic translation initiation factor 2-α kinase 1), have not, to our knowledge, been previously suspected to play a role in the prediction of IFN-β sensitivity/resistance, chemotherapy resistance, prognosis, tumor progression, or antiproliferation. The PTEN and EIF2AK1 expression levels showed significant negative and positive correlations with IFN-β sensitivity/resistance, respectively (Figs. 2 and 3) . AM-38, 92,800; T98G, 179,000; U-87MG, 61,700; U-251MG, 30,300; and YH-13, 224,000 pmol/dl). The 2'5'OAS activity levels at 24 h after 10 IU/ml IFN-β administration increased in a widely varied manner, ranging from 691,000 in U-138MG to 6,970,000 pmol/dl in A-172. The 2'5'OAS activity levels and response ratios (measured value/measured value of control 2'5'OAS) at 24 h in all the cell lines including U-138MG were dose-dependently increased by IFN-β (Fig. 4) . However, the 2'5'OAS activity levels in U-138MG at 24 h after 1, 10 and 100 IU/ml IFN-β treatment were 137,000 (response ratio: 30.79), 691,000 (155.28) and 2,190,000 (492.13) pmol/dl, respectively, and these response ratios were very high as compared to the other six cell lines. With the exception of U-138MG, therefore, the 2'5' OAS response ratio appeared to be related to the IFN-β sensitivity/resistance, the IC 75 of IFN-β, although there was no statistical significance (Pearson's corre lation coefficients (r) and corresponding P-values). We divided the seven malignant glioma cell lines into two groups according to the presence (A-172 and T98G) or absence (AM-38, U-87MG, U-251MG, U-138MG and YH-13) of a synergistic effect of combination therapy with TMZ and IFN-β. U-138MG was excluded from the next analysis of data because its did not reach its IC 75 with 0.1-1,000 IU/ml of IFN-β treatment. Tables IV and V have not, to our knowledge, been previously suspected to play a role in the prediction of chemotherapy resistance, prognosis, tumor progression, or antiproliferation. However, five genes [namely, Wilms' tumor 1 (WT1), S-phase kinase-associated protein 1 (SKP1), TP53 apoptosis effector (PERP), Janus-activated kinase 2 (JAK2) and autophagy-related 5 homolog (ATG5)] have previously been reported to be associated with such processes (Table VI, Fig. 6 ). The gene-specific information was retrieved from Entrez Gene: gene-centered information at NCBI (22) .
IFN-β induction of 2'5'OAS activity in malignant glioma
Discussion
It is possible that large-scale gene expression analysis, rather than analysis of single genes or pathways, can yield a more robust predictor of responses to chemotherapy in tumors, since their sensitivity/resistance may be complex with multiple mechanisms and involve many genes (16, 23) . Moreover, with the variable responses to chemotherapy in tumors, the clinical therapeutic outcome tends to be determined after a relatively long-term treatment, so that early marker(s) of treatment sensitivity/resistance are required. Such marker(s) would help to improve patient care, allowing the rapid selection of effective drug(s) and equally the exclusion of ineffective drug(s), with time-saving consequences, and a more efficient use of resources (24) . We therefore evaluated the gene expression profiles employing GeneChip in seven malignant human glioma-derived cell lines in an attempt to identify new marker(s) that could be applied clinically to predict the response to therapy and new target gene(s) for the therapy related to malignant glioma pathogenesis. One purpose of the present study was to identify molecular marker(s) that reflected therapeutic responses to the direct antitumor effect of IFN-β in malignant glioma cells, since IFN-β is known to be partially effective for treating malignant glioma patients; clinical trials of IFN-β have resulted in partial remission in 50% or more of patients tested (25, 26) , and the pharmaco-dynamics at the genomic level in humans remain poorly understood. To our knowledge, this is the first report on gene expression profiles to identify marker(s) that could be used clinically to predict malignant gliomas responses to IFN-β. The classification of the IFN family of proteins is based mainly on their sequence, chromosomal location and receptor specification (27) . IFNs are classified into three major groups: type I, II and III. Type I IFNs include IFN-α, -β, -ω, -ε and -κ. The human type I IFN family includes 13 IFN-α genes, one IFN-β gene and two IFN-ω genes (27) . It is now accepted that most nucleated cells are capable of producing type I IFN, whereas type II IFN production is restricted to immune system cells (5) . All members of the type I IFN family transmit signals through a receptor complex composed of two subunits, IFNAR-1 and IFNAR-2. In response to the different types of IFNs, members of the signal transducer and activator of transcription (STAT) family are activated through tyrosine phosphorylation, by the JAK family, which leads to their homo-or hetero-dimerization, nuclear translocation and transcription of IFN-stimulated genes (ISGs). The transcriptional regulation of effector genes downstream to the JAK/ STAT or other IFN-regulated pathways contributes to the pleiotropic responses induced by IFNs (27) . It is conceivable that numerous direct effects may play a central role in the overall antitumor response, such as downregulation of oncogene expression, induction of differentiation, tumor suppressor genes and programmed cell death, and inhibition of cell cycle progression (5). Furthermore, IFN-β has consistently been proven to be more potent than IF Ns-α in inducing antiproliferative effects and apoptosis (5, 28) .
In the present report, the highly significant statistically positive-and negative-correlation genes associated with IFN-β sensitivity/resistance are listed in Tables II and III. To our knowledge, six of the eight genes have not previously been suspected to be related to IFN-β, chemotherapy resistance, prognosis, tumor progression, or antiproliferation. The other two genes, one upregulated gene, PTEN, and one downregulated gene, EIF2AK1, have previously been reported to be associated with such processes. Although the underlying mechanism of these genes that confers IFN-β sensitivity/resistance remains to be fully elucidated, the following facts could lend support to our results and suggest alternative therapeutic rationales as part of a new biomolecular approach to the treatment of malignant gliomas. PTEN is one of the most frequent mutated genes in human cancers. The frequency of PTEN mutations in glioblastomas is ~30%, varying from 9 to 44% (29) . The potential protein targets of PTEN range from membrane-bound receptor tyrosine kinases and cytoplasmic signaling molecules to transcription factors in the nucleus. The phosphoinositol-3-kinase (PI3-kinase)/AKT pathway is regarded as the primary physiological target of PTEN. Phosphatase activity, particularly lipid phosphatase activity, is believed to be the most pertinent property of PTEN as a tumor suppressor (29) . Indeed, overexpression of wild-type PTEN in tumor cells induces apoptosis and cell cycle arrest, colony formation and cell migration (29) (30) (31) (32) . In particular, high nuclear PTEN levels have been found to be associated with the G0-G1 phase and lower nuclear PTEN levels with the S phase, implying that nuclear PTEN activity might directly regulate the cell cycle (33) . It has been suggested therefore that PTEN acts on chromatin and regulates the transcription of important genes involved in critical cellular processes such as cell cycle control and DNA repair (29) . On the other hand, p53 is the most frequently mutated gene in human tumors; and in terms of overall frequency, PTEN is the second most commonly mutated gene in human tumors. However, the mutation spectra of p53 and PTEN in human tumors are different. Mutations of p53 occur at high frequencies in lung, colon and breast cancers, whereas PTEN mutations are found mostly in glioblastomas, endometrial cancers, malignant melanomas and prostate cancers (29) . In their role as the autonomic surveillance and defense systems to genomic instability and tumorigenesis, tumor suppressors act in coordination with each other to form regulatory networks (29) . The existence of relationships between PTEN and p53 is thus an intriguing and theoretically attractive question. Studies on their spectra of mutations have revealed that PTEN and p53 are usually independent and mutually exclusive (29, 34) . Furthermore, the p53 protein is maintained at low levels in normal cells and its induction requires stimulation upon cellular stress, whereas PTEN expression levels are steady and high in normal cells and maintenance of its abundance is important for sustaining its function in safeguarding the genome (29) . On the other hand, PTEN has been reported as a downstream transcriptional target of p53 in mediating apoptosis (29) . It has also been suggested that PTEN may act upstream of p53 to regulate its expression levels and activity (29, 35, 36) . Furthermore, transcription of the p53 gene can be induced by IFN-α/β in tumors, accompanied by an increase in p53 protein level (37) . The above findings indicate that these two guardians of the genome, PTEN and p53, may act to complicate the antitumor effect of IFN-β in malignant gliomas.
The proteins with important biological functions that are induced by IFNs include two double-stranded RNA-activated enzymes: double-stranded RNA-dependent protein kinase (PKR) and 2'5'OAS (21) . When an antiviral pathway is induced by IFNs or activated by double-stranded RNA, the PKR becomes autophoshorylated and catalyzes phosphorylation of the protein synthesis initiation factor EIF2 (eukaryotic translation initiation factor 2), while the 2'5'OAS forms 2'5'OA molecules that activate the latent endoribonuclease, RNase L; the PKR/EIF2 and 2'5'OAS/RNase L pathways, respectively (21, 38) . These enzymes are also implicated in the regulation of other cellular events, such as gene induction, normal control of cell growth, differentiation and apoptosis (21, 38, 39) .
The other noteworthy gene in the present study that may be involved in conferring IFN-β sensitivity/resistance is EIF2AK1; the PKR/EIF2 pathway. PKR, namely eukaryotic translation initiation factor 2-α kinase (EIF2AK), can inhibit overall protein synthesis via phosphorylation of the α subunit of eukaryotic initiation factor 2, EIF2A. Such regulation of translation may potentially play an important role in apoptosis induction (21) . To distinct degrees, at least EIF2A, NF-κB, ATF-3 and p53 have been implicated in mediating PKRinduced apoptosis (40) . As a consequence of the effects of PKR on translation, transcription and apoptosis, PKR can function to control cell growth and cell differentiation, and its activity can be controlled by the action of several tumorigenes (40) . The other pathway among the proteins with important biological functions induced by IFNs, as described above, is the 2'5'OAS/RNase L pathway. 2'5'OAS is specifically induced by viral infection or extracellular introduction of IFN and plays an important role in molecular events that lead to the antiviral action provoked by IFN in the host cells (19) . Indeed, based on the clinical observation in chronic hepatitis C patients that the serum 2'5'OAS level is generally increased on administration of IFN, the serum level of this enzyme has been used as a clinical marker to predict the responsiveness of the host to IFN (19, 21) . However, there are few data concerning the detailed role of 2'5'OAS in malignant glioma cells. Therefore, to investigate whether or not IFN-β could induce antiviral proteins, 2'5'OAS in malignant glioma cells, the 2'5'OAS activity was determined at 24 h after incubation with IFN-β. Although the reason remains unclear, the 2'5'OAS level before IFN-β treatment in the U-138MG cell line, which did not reach its IC 75 with 0.1-1,000 IU/ml of IFN-β, was very low compared to that of the other six cell lines. The levels of 2'5'OAS activity and response ratio (measured value/measured value of control 2'5'OAS) in all the glioma cell lines were dose-dependently increased by IFN-β. Furthermore, the 2'5'OAS response ratio was closely related to IFN-β sensitivity/ resistance, the IC 75 of IFN-β, but not statistically significant (Fig. 4) . Although the pretreatment value and response ratio of 2'5'OAS activity appear to be important factors for IFN-β sensitivity/resistance, the present results suggest that measurement of the 2'5'OAS activity might be a useful parameter for assessing the response to IFN-β treatment not only in virus infections but also in malignant gliomas, and could help to resolve the question of the optimal dose and schedule of IFN-β treatment.
On the other hand, we demonstrated a sensitization of glioma cells to the TMZ-induced antitumor effect of IFN-β in the A-172 and T98G cell lines. Our prior studies have shown that T98G, U-138MG and YH-13 had MGMT mRNA and protein expression, whereas A-172, AM-38, U-87MG and U-251 did not have them (3) . Further, a synergistic antitumor effect of combination treatment with IFN-β and TMZ was observed in the TMZ-resistant glioma cells, T98G, due possibly to an attenuation of their MGMT mRNA levels (12) . However, in the present study, other MGMT-positive cell lines, at least YH-13, did not exhibit a synergistic effect between IFN-β and TMZ, whereas the MGMT-negative cell line, A-172, displayed a synergistic effect with a combination of TMZ and IFN-β. Thus, the synergistic effect of TMZ and IFN-β may not be limited to MGMT-negative or -positive cell lines, suggesting that IFN-β might represent a powerful agent for increasing the benefit from TMZ in certain malignant gliomas. Many upregulated and downregulated genes associated with the synergistic effect between TMZ and IFN-β are listed in Tables IV and V. To our knowledge, most of the genes in these tables have not previously been suspected to be related to chemotherapy resistance, prognosis, tumor progression, or antiproliferation, in gliomas. However, five genes, three upregulated genes (WT1, SKP1 and PERP) and two downregulated genes (JAK2 and ATG5), have previously been reported to be associated with such processes. In particular, the noteworthy genes that may be involved in conferring the synergistic effect between TMZ and IFN-β are WT1 and JAK2.
Although WT1, the Wilms' tumor gene, was originally isolated as a tumor-suppressor gene that was inactivated in a subset of Wilms' tumors, a common pediatric kidney cancer, it was later found to be overexpressed in many types of tumors, including breast carcinomas, acute leukemia and glioblastomas (41, 42) . It was proposed therefore that the wild-type WT1 gene may play an oncogenic role rather than a tumor-suppressor role in the tumorigenesis of various types of tumors. Recent studies have indicated that the WT1 gene plays an important role in the tumorigenesis of malignant gliomas and suggested that WT1 may represent a new molecular target for the treatment of malignant gliomas expressing WT1 (41, 42) . JAK2 is one member of a family of four cytoplasmic tyrosine kinases that also includes JAK1, JAK3 and Tyk2 (tyrosine kinase 2) (43). JAK2 can phosphorylate EGFR (epidermal growth factor receptor) to activate the mitogen-activated protein kinase (MAPK) pathway (44) . STAT3, which can be activated by JAK2, EGFR and other tyrosine kinases, is a center for many signaling pathways. It plays a crucial role in tumorigenesis, and efforts are ongoing to target it in antitumor drug developments (45, 46) . The above characterizations of the molecular targets implicated in the sensitivity/resistance of combination therapy with IFN-β and TMZ are considered valuable at least in helping to refine the therapeutic benefits of TMZ for malignant gliomas in the near future.
Finally, several limitations and implications of the present study will be briefly discussed. First, the criticism can always be made that the expression profiles of cell lines do not exactly represent the genetic events that occur in actual tumors. Second, the present study was restricted to the use of only seven malignant glioma-derived cell lines, and because of the heterogeneity of the disease, this was not sufficient to provide a conclusive picture of the mechanism of action. Third, it is possible that if the entire genome were to be analyzed, the number of potential molecular markers for treatment and chemotherapy targets would increase. Fourth, in general, the gene expression correlates of drug sensitivity/resistance tend to be complex, and their biological significance is not easily interpretable. Although larger experiments are needed to confirm our findings, the data do identify genes and pathways that could not only be potential molecular markers but also attractive targets for therapeutic modulation of malignant gliomas. Furthermore, the present study may provide a foundation for treatments that could improve the outcome by devising strategies that are able to circumvent primary drug resistance in malignant gliomas.
